Using the FDA’s Adverse Event Joyce Weaver, Pharm.D., B.C.P.S.
Reporting System (AERS) in Safety Evaluator,
Postmarketing Surveillance Division of Drug Risk Evaluation
Epidemiologic Analysis of Mary Willy, Ph.D.
Spontaneous Adverse Reports Epidemiology Team Leader,
Using FDA’s AERS in Postmarketing Carol Holquist, R.Ph
Surveillance for Medication Errors Director
Support (DMETS), ODS
Available Types of National Judy Staffa, Ph.D., R.Ph.
Drug Use Data Epidemiology Team Leader,
Communication Support (DSRCS), ODS
Issues in the Practical Application of A. Lawrence Gould, Ph.D.
Data Mining Techniques to Senior Director, Scientific Staff,
Pharmacovigilance Biostatistics and Research Decision Sciences
Data Mining AERS, FDA’s Carolyn McCloskey, M.D., M.P.H.
(Spontaneous) Adverse Event Epidemiologist
Reporting System DDRE, ODS
Open Public Hearing Speakers
Charles L. Bennett, M.D., Ph.D., MPP
Feinberg School of Medicine, Northwestern University
Midwest Center for Health Services Policy Research
Alexander M. Walker, M.D., DR.PH
Sr VP Epidemiology
Active Surveillance for Drug Safety Mary Willy, Ph.D.
Signals: Past, Present and Future Epidemiology Team Leader
*NEISS:CADES Active Surveillance Aaron Mendelsohn, Ph.D., M.P.H.
Active Surveillance Using Longitudinal David Graham, M.D., M.P.H.
Data: A Pilot Project Medical Officer, OPaSS
Questions to the Committee